Evidence supporting the use of: Bifidobacterium breve
For the health condition: Allergies (food)

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Bifidobacterium breve has some scientific evidence supporting its use in the management of food allergies, especially in children, although the evidence is not robust. Several studies have investigated the ability of B. breve to modulate the immune system by promoting regulatory T-cell responses and enhancing the intestinal barrier, which may help reduce allergic sensitization. Some randomized controlled trials (RCTs) have shown that supplementation with B. breve (often in combination with other probiotic strains) can improve symptoms in infants and children with cow’s milk allergy, such as reducing eczema severity and improving tolerance to cow’s milk protein. For example, a well-cited study by Baldassarre et al. (2010) reported that B. breve supplementation helped accelerate the acquisition of tolerance to cow’s milk protein in allergic infants. However, results are inconsistent across studies and often involve multi-strain probiotic mixtures, making it difficult to attribute the benefit to B. breve alone. Current clinical guidelines do not universally endorse probiotics, including B. breve, as a primary treatment for food allergies, but they acknowledge their potential as adjunct therapies. Overall, while there is some scientific rationale and preliminary evidence for using B. breve in food allergy management, more high-quality, strain-specific research is needed to establish its efficacy and clarify its role in clinical practice.

More about bifidobacterium breve
More about Allergies (food)